The Efficacy and Safety of Combination Therapy with Alpha-Blocker and Low-Dose Propiverine Hydrochloride for Benign Prostatic Hyperplasia Accompanied by Overactive Bladder Symptoms.
10.4111/kju.2009.50.11.1078
- Author:
Kang Il SEO
1
;
Sung Zoo HONG
;
Jong Bouk LEE
Author Information
1. Department of Urology, National Medical Center, Seoul, Korea. nmcuro@hanmail.net
- Publication Type:Original Article
- Keywords:
Prostatic hyperplasia;
Overactive urinary bladder
- MeSH:
Benzilates;
Cholinergic Antagonists;
Humans;
Lower Urinary Tract Symptoms;
Male;
Prospective Studies;
Prostate;
Prostatic Hyperplasia;
Quality of Life;
Residual Volume;
Sulfonamides;
Urinary Bladder, Overactive
- From:Korean Journal of Urology
2009;50(11):1078-1082
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We evaluated the efficacy and safety of combined therapy with an alpha-blocker (tamsulosin 0.2 mg) and low-dose anti-cholinergics (propiverine HCl 10 mg) in patients with benign prostatic hyperplasia (BPH) accompanied by overactive bladder (OAB) symptoms. MATERIALS AND METHODS: This prospective study enrolled 119 male patients with lower urinary tract symptoms (LUTS) with prostate volume of 20 ml or greater, International Prostate Symptom Score (IPSS) of more than 8, and OAB symptoms from May 2007 to April 2008. Patients with post-void residual volume (PVR) over 100 ml were excluded. Among these patients, 74 patients were treated with tamsulosin 0.2 mg plus propiverine HCl 10 mg (group A) and 45 patients were treated with tamsulosin 0.2 mg only (group B). The clinical parameters, including IPSS, quality of life (QoL) score, uroflowmetry, and PVR were re-evaluated after 3 months. RESULTS: A total of 115 patients, including 70 in group A and 45 in group B, completed the study. IPSS, QoL score, voided volume, maximum flow rate (Qmax), and PVR showed significant improvement after 3 months of treatment (p<0.05). Baseline characteristics between the 2 groups were not significantly different for any parameter (p>0.05). Changes in the QoL score were -1.9+/-1.1 and -1.5+/-0.9 for group A and group B, respectively (p=0.043). Changes in all other parameters were not significantly different between the 2 groups (p>0.05). CONCLUSIONS: For those patients with LUTS due to BPH and concomitant OAB, combination therapy with an alpha-blocker (tamsulosin 0.2 mg) and low-dose anti-cholinergics (propiverine HCl 10 mg) may be a reasonable and effective therapeutic option as an initial therapy.
